Determination of lamivudine, zidovudine, and nevirapine in capillary blood sampled on filter paper by LC

Journal of Chromatographic Science

Volumn 47, Issue 10, 2009, Pages 855-862

  Malm, M ^a,b   Romsing S ^a,b,c   Obua, C ^d   Bergqvist, Y ^a,b  

^a DALARNA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Center for Clinical Research Dalarna   (Sweden)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450179300     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/47.10.855     Document Type: Article

References (33)

1. UNAIDS. AIDS epidemic update: December 2006. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); Geneva, 2006.
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 rev. World Health Organization; Geneva, 2006.
3. D. Back, S. Gibbons, and S. Khoo. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28: 468-473 (2006).
4. R.E. Aarnoutse, J.M. Schapiro, C.A. Boucher, Y.A. Hekster, and D.M. Burger. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63: 741-753 (2003).
5. NNRTI/NRTI Drug Interactions. 2007 [cited 2007 October 15]; Available from: www.hiv-druginteractions.org.
6. C.V. Fletcher, S.P. Kawle, T.N. Kakuda, P.L. Anderson, D. Weller, L.R. Bushman, R.C. Brundage, and R.P. Remmel. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. Aids 14: 2137-2144 (2000).
7. D.T. Holland, R. DiFrancesco, J.D. Connor, and G.D. Morse. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther. Drug Monit. 28: 367-374 (2006).
8. W.W. Bond, M.S. Favero, N.J. Petersen, C.R. Gravelle, J.W. Ebert, and J.E. Maynard. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1: 550-551 (1981).
9. Guidelines for the Shipment of Dried Blood Spot Specimens. CDC: Centers for Disease Contol and Prevention. (1993).
10. B. Evengard, A. Ehrnst, M. von Sydow, P.O. Pehrson, P. Lundbergh, and E. Linder. Effect of heat on extracted HIV viral infectivity and antibody activity using the filter paper technique of blood sampling. Aids 3: 591-595 (1989).
11. H.A. Goubran, T. Burnouf, and M. Radosevich. Virucidal heat-treatment of single plasma units: a potential approach for developing countries. Haemophilia 6: 597-604 (2000).
12. H.N. Mistri, A.G. Jangid, A. Pudage, N. Gomes, M. Sanyal, and P. Shrivastav. High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853: 320-332 (2007).
13. S. Compain, D. Schlemmer, M. Levi, A. Pruvost, C. Goujard, J. Grassi, and H. Benech. Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices. J. Mass Spectrom. 40: 9-18 (2005).
14. S. Notari, A. Bocedi, G. Ippolito, P. Narciso, L.P. Pucillo, G. Tossini, R.P. Donnorso, F. Gasparrini, and P. Ascenzi. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 831: 258-266 (2006).
15. C.P. Verweij-van Wissen, R.E. Aarnoutse, and D.M. Burger. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 816: 121-129 (2005).
16. G. Ramachandran, A.K. Hemanthkumar, V. Kumaraswami, and S. Swaminathan. A simple and rapid liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 843: 339-344 (2006).
17. B. Fan and J.T. Stewart. Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J. Pharm. Biomed. Anal. 28: 903-908 (2002).
18. J.V. Mei, W.H. Hannon, T.L. Dobbs, C.J. Bell, C. Spruill, and M. Gwinn. Radioimmunoassay for monitoring zidovudine in dried blood spot specimens. Clin. Chem. 44: 281-286 (1998).
19. T. Koal, H. Burhenne, R. Romling, M. Svoboda, K. Resch, and V. Kaever. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19: 2995-3001 (2005).
20. Guidance for industry, bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). (2001).
21. B. Boulanger, P. Chiap, W. Dewe, J. Crommen, and P. Hubert. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. J. Pharm. Biomed. Anal. 32: 753-765 (2003).
22. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 75: 3019-3030 (2003).
23. B.L. Robbins, P.A. Poston, E.F. Neal, C. Slaughter, and J.H. Rodman. Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 850: 310-317 (2007).
24. L.S. Rowland, T.R. MacGregor, S.J. Campbell, R. Jenkins, A.B. Pearsall, and J.P. Morris. Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 856: 252-260 (2007).
25. R.M. van Praag, E.C. van Weert, R.P. van Heeswijk, X.J. Zhou, J.P. Sommadossi, S. Jurriaans, J.M. Lange, R.M. Hoetelmans, and J.M. Prins. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob. Agents Chemother. 46: 896-899 (2002).
26. M.C. Hosseinipour, A.H. Corbett, C. Kanyama, I. Mshali, S. Phakati, N.L. Rezk, C. van der Horst, and A.D. Kashuba. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. Aids 21: 59-64 (2007).
27. G.J. Yuen, Y. Lou, N.F. Thompson, V.R. Otto, T.L. Allsup, W.B. Mahony, and H.W. Hutman. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. 41: 277-288 (2001).
28. J.P. Sabo, M.J. Lamson, G. Leitz, C.L. Yong, and T.R. MacGregor. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci. 2: E1 (2000).
29. T.N. Kakuda, L.M. Page, P.L. Anderson, K. Henry, T.W. Schacker, F.S. Rhame, E.P. Acosta, R.C. Brundage, and C.V. Fletcher. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45: 236-242 (2001).
30. R.P. van Heeswijk, A.I. Veldkamp, J.W. Mulder, P.L. Meenhorst, F.W. Wit, J.M. Lange, S.A. Danner, N.A. Foudraine, M.O. Kwakkelstein, P. Reiss, J.H. Beijnen, and R.M. Hoetelmans. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Aids 14: F77-82 (2000).
31. S.R. Penzak, G. Kabuye, P. Mugyenyi, F. Mbamanya, V. Natarajan, R.M. Alfaro, C. Kityo, E. Formentini, and H. Masur. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8: 86-91 (2007).
32. M.M. de Maat, J.H. Beijnen, J.H. Schellens, and J.W. Mulder. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. J. Infect. 50: 262-264 (2005).
33. A.I. Veldkamp, G.J. Weverling, J.M. Lange, J.S. Montaner, P. Reiss, D.A. Cooper, S. Vella, D. Hall, J.H. Beijnen, and R.M. Hoetelmans. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. Aids 15: 1089-1095 (2001).